

TTSH International Normalised Ratio (INR) Remote Monitoring (RM) Service

K.X. Ong¹, W.Q. Ten^{1,} C.H. Choo¹ ¹Division of Pharmacy Clinical Services



Adding years of healthy life

Mission Statement

Increase uptake for RM of INR among TTSH Pharmacists-run Anticoagulation Clinic (ACC) patients by at least 50% in number of visits from January 2021 to December 2022

Aims and objectives

From January 2021 to December 2022:

- To increase uptake for RM of INR among TTSH ACC patients by ≥50% in number of visits
- 2. To validate that RM of INR is also able to achieve ≥60% of INR within therapeutic range, comparable to face-to-face (F2F) ACC visits

	Name	Designation	Department	
Team Leader	Ong Kai Xin	Principal Pharmacist (Clinical)		
Team Members	Choo Chor Hui, Theresa	Principal Pharmacist (Clinical)		
	Shaun Eric Lopez	Senior Pharmacist (Clinical)	Pharmacy	
	Rachel Lim Xue Ting	Senior Pharmacist		

Team Members

Ten Wei Qing

Background

Warfarin is a blood thinner and is the mainstay in the treatment and prevention of thromboembolic complications. Warfarin dose is adjusted using INR blood test. Frequent monitoring of INR is often required.

There were numerous feedback from patients about the hassle of returning to hospital for frequent INR blood tests and attending ACC appointments.

RM of INR was explored as a potential solution to ease warfarin patients' care journey.

History of TTSH ACC INR Remote Monitoring Service


Year
2012
Launch of RM service: Loan of home POCT (Point-of-care-testing) INR meters to patients requiring frequent INR checks.
Patients self-performed INR test at home followed by teleconsultation with pharmacist.



Implementation and Partnership

We started exploring partnership with different community healthcare partners from 2020 to increase the number of avenues in which patients can have their INR drawn. With an increase in accessibility for patient's INR to be drawn followed by ACC teleconsultation at an agreed timing, we work towards increasing patient's adherence to consultations and warfarin therapy.





March 2021





New service level agreement (SLA) with **NHG Diagnostics** to allow INR blood test to be taken at NHG Polyclinics

- Patients can travel to nearby NHG Polyclinics with ACC memo and blood test form
- NHG Diagnostics perform INR blood taking and run blood specimen

INR blood taking expanded to **General Practitioners (GP), other tertiary institutions** i.e. IMH and nursing homes


- Patients from these tertiary institutions can have their venous PT-INR drawn by in-house nurses
- In-house or external laboratory runs blood specimen

Collaborated with home care partner, Active Global, for INR to be drawn at home.

September 2022

- Home care nurses travel to patients' homes to draw venous PT-INR
- External laboratory runs blood specimen


Results



TTSH COVID-19 cluster outbreak on 28 April 2021 has facilitated the push for RM and teleconsultations with the ramping down of physical clinics.

There is an annual increase in number of RM visits of 435% from 2020 to 2021. It then sustained at 375% from 2020 to 2022.

	Year 2019	Year 2020	Year 2021	Year 2022
Number of RM visits	26	68	364	323
% within therapeutic INR range for RM visits	70%	70.8%	66.9%	60.3%



Between Year 2019 and 2023, the average % within therapeutic INR range for F2F visits was 64.55%

Benefits of Remote Monitoring: Time Saving

Per patient: Typical wait time for a F2F physical ACC consultation





RM patients are seen at allocated timing and medicines are delivered to them. This reduces the need to wait for consultation and medication. Average time saved per RM patient: 74 minutes per visit; total time savings of 448 hours (in 2021) and 398 hours (in 2022)!

Conclusion

RM has demonstrated *Better Care* (patients reviewed at their convenient time and place), *Better Community* (collaboration with community partners), *Better Health* (RM encourages compliance for routine INR checks and warfarin titrations and hence better attainment of therapeutic INRs; this translates to lower bleeding and thromboembolic risks) and *Better Value* (RM patients getting the same clinical care as F2F ACC visit patients).